NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total value of $90,055.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) traded up $0.11 on Friday, reaching $25.99. The company had a trading volume of 275,240 shares, compared to its average volume of 569,230. NxStage Medical, Inc. has a 12 month low of $20.45 and a 12 month high of $30.80.
NXTM has been the subject of a number of research reports. Leerink Swann downgraded NxStage Medical from an “outperform” rating to a “market perform” rating and increased their target price for the company from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Zacks Investment Research downgraded NxStage Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Northland Securities reiterated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Wednesday, November 8th. William Blair downgraded NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $30.25.
A number of institutional investors and hedge funds have recently modified their holdings of NXTM. BlackRock Inc. lifted its position in NxStage Medical by 38,360.4% in the first quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock worth $118,408,000 after buying an additional 4,401,851 shares during the last quarter. Alpine Associates Management Inc. bought a new stake in NxStage Medical in the third quarter worth $110,163,000. Magnetar Financial LLC bought a new stake in NxStage Medical in the third quarter worth $84,927,000. FMR LLC lifted its position in NxStage Medical by 31.8% in the second quarter. FMR LLC now owns 9,860,278 shares of the medical device company’s stock worth $247,197,000 after buying an additional 2,378,077 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in NxStage Medical by 239,738.6% in the third quarter. JPMorgan Chase & Co. now owns 1,870,741 shares of the medical device company’s stock worth $51,502,000 after buying an additional 1,869,961 shares during the last quarter. Institutional investors own 92.31% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.